News for Assembly Biosciences, Inc. (ASMB)

”“ Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 ”“ ”“ Biomarker of

On February 18, 2025, Gilead Sciences, Inc. executed a significant stock transaction involving Arcus Biosciences Inc (RCUS). The firm added 9,630,525 shares of

On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio) executed a strategic transaction involving Assembly Biosciences Inc (ASMB), reducing its holdin

D.E. Shaw To Return Billions After Flagship Hedge Fund Gains 18% (Bloomberg) Two Sub-$100 Warren Buffett Stocks To Buy And Hold For Long-Term (Finbold) Bill Ackman’s Pershing Square Fund To De-List From Amsterdam Stock Exchange (Billboard.

The S&P 500 futures are down 19 points, the Nasdaq 100 futures are down 75 points, and the Dow Jones Industrial Average futures are down 139 points, indicating

Assembly Biosciences (ASMB) stock gains on interim data from a Phase 1 trial for its hepatitis B treatment ABI-4334 developed with Gilead (GILD). Read more here.

”“ ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed ”“ ”“ In the first 150 mg dose coho

Gilead Sciences invests $20.1 million in Assembly Biosciences

Assembly Biosciences (ASMB) stock gains as Gilead Sciences (GILD) increases stake to ~30% with $20.1M investment. Read more here.

Revenue: $6.8 million for Q3 2024, falling short of the estimated $8.64 million, but marking an increase from no revenue in the same period last year.Net Loss:

Assembly Biosciences keeps Neutral rating after Phase 1a study results

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Loading... Loading... Although U.S. stocks closed mixed on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their ...

London-based VivoPower International PLC (VVPR) is up over 121 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion.

/PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced...

SkyQuest's Microbiome Market report provides actionable insights for individuals interested in valuable data, trends, and opportunities in a rapidly...

While the market driven by short-term sentiment influenced by the accommodative interest rate environment in the US, virus news and stimulus spending,...

SOUTH SAN FRANCISCO, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology compan...